Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3)

Brazil flag Brazil · Delayed Price · Currency is BRL
1.180
+0.120 (11.32%)
Jun 17, 2026, 5:05 PM GMT-3
Market Cap1.32B -58.3%
Revenue (ttm)5.41B -13.7%
Net Income-3.84B
EPS-4.10
Shares Out 1.12B
PE Ration/a
Forward PE8.43
Dividendn/a
Ex-Dividend Daten/a
Volume13,776,200
Open1.090
Previous Close1.060
Day's Range1.060 - 1.190
52-Week Range0.990 - 6.000
Beta0.88
AnalystsSell
Price Target2.48 (+110.17%)
Earnings DateAug 6, 2026

About BVMF:ONCO3

Oncoclínicas do Brasil Serviços Médicos S.A., together with its subsidiaries, provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America. The company offers treatment services, including radiotherapy, hormone therapy, immunotherapy, port-a-cath, palliative care, target therapy, breast cancer hormone therapy, bone marrow transplant, non-oncological infusions, oral chemotherapy, and prostate cancer hormone therapy; and surgery procedures, such as breast, head and neck, lung, prostate cancer, stomach, bladder ca... [Read more]

Sector Healthcare
Founded 2010
Country Brazil
Stock Exchange Brazil Stock Exchange
Ticker Symbol ONCO3
Full Company Profile

Financial Performance

In 2025, BVMF:ONCO3's revenue was 5.74 billion, a decrease of -7.83% compared to the previous year's 6.23 billion. Losses were -3.62 billion, 460.8% more than in 2024.

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for ONCO3 stock is "Sell." The 12-month stock price target is R$2.48, which is an increase of 110.17% from the latest price.

Price Target
R$2.48
(110.17% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Oncoclínicas do Brasil Serviços Médicos Earnings Call Transcript: Q1 2026

Q1 2026 saw operational and financial pressures, with revenue hit by medication shortages and a one-time spike in doubtful accounts provisioning. Cost controls and capital discipline are underway, but leverage increased and cash flow was negative.

4 weeks ago - Transcripts

Oncoclínicas do Brasil Serviços Médicos Earnings release: Q1 2026

Oncoclínicas do Brasil Serviços Médicos released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.

4 weeks ago - Filings

Oncoclínicas do Brasil Serviços Médicos Slides: Q1 2026

Oncoclínicas do Brasil Serviços Médicos has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 15, 2026.

4 weeks ago - Filings

Oncoclínicas do Brasil Serviços Médicos Earnings Call Transcript: Q4 2025

Leadership transition and strategic refocus led to a 7% revenue decline and over 30% drop in EBITDA, driven by major client losses and liquidity events. Debt restructuring and asset sales are underway, with ongoing creditor negotiations.

2 months ago - Transcripts

Oncoclínicas do Brasil Serviços Médicos Earnings release: Q4 2025

Oncoclínicas do Brasil Serviços Médicos released its Q4 2025 earnings on April 10, 2026, summarizing the period's financial results.

2 months ago - Filings

Oncoclínicas do Brasil Serviços Médicos Slides: Q4 2025

Oncoclínicas do Brasil Serviços Médicos has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on April 10, 2026.

2 months ago - Filings

Oncoclínicas do Brasil Serviços Médicos Earnings Call Transcript: Q3 2025

Significant restructuring and a BRL 1.4 billion capital increase enabled a return to core oncology, improved margins, and reduced leverage. Asset sales and operational efficiencies drove sequential EBITDA and cash flow gains, with guidance for double-digit growth and lower CapEx.

7 months ago - Transcripts

Oncoclínicas do Brasil Serviços Médicos Earnings release: Q3 2025

Oncoclínicas do Brasil Serviços Médicos released its Q3 2025 earnings on November 17, 2025, summarizing the period's financial results.

7 months ago - Filings

Oncoclínicas do Brasil Serviços Médicos Slides: Q3 2025

Oncoclínicas do Brasil Serviços Médicos has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 17, 2025.

7 months ago - Filings

Oncoclínicas do Brasil Serviços Médicos Earnings Call Transcript: Q2 2025

Q2 2025 saw stable gross revenue and a 38.3% sequential rise in adjusted EBITDA, but net loss and negative cash flow persisted due to client discontinuations and high financial expenses. Revenue is expected to decelerate in Q3 as major contracts end, but new client growth and margin recovery are anticipated.

10 months ago - Transcripts

Oncoclínicas do Brasil Serviços Médicos Earnings release: Q2 2025

Oncoclínicas do Brasil Serviços Médicos released its Q2 2025 earnings on August 15, 2025, summarizing the period's financial results.

10 months ago - Filings

Oncoclínicas do Brasil Serviços Médicos Slides: Q2 2025

Oncoclínicas do Brasil Serviços Médicos has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 15, 2025.

10 months ago - Filings